Study of lung cancer treatment costs may point to savings on a broader scale

Rafuse, Jill
October 1993
CMAJ: Canadian Medical Association Journal;10/15/1993, Vol. 149 Issue 8, p1162
Academic Journal
No abstract available.


Related Articles

  • Prevention praised, cure preferred: results of between-subjects experimental studies comparing (monetary) appreciation for preventive and curative interventions. Meertens, Ree M.; Van de Gaar, Vivian M. J; Spronken, Maitta; de Vries, Nanne K. // BMC Medical Informatics & Decision Making;2013, Vol. 13 Issue 1, p1 

    Background 'An ounce of prevention is worth a pound of cure' is a common saying, and indeed, most health economic studies conclude that people are more willing to pay for preventive measures than for treatment activities. This may be because most health economic studies ask respondents to...

  • Individualizing Treatment Strategies in the Management of Advanced NSCLC. Reddy, Sandeep // Journal of Managed Care Medicine;2013, Vol. 16 Issue 1, p30 

    The article discusses a study that was conducted to understand the basic biology of lung cancer with the help of individualized treatment strategies which is a leading personalized therapy that is used in the management of advanced non-small cell lung cancer (NSCLC). It mentions the cost of...

  • Lung cancer screening, early treatment well worth it in Canada.  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 710 Issue 1, p15 

    The article discusses the results of a prospective resource use and cost analysis of the Pan-Canadian Early Detection of Lung Cancer Study that reveal lower average cost of screening individuals with a high risk of lung cancer and initial curative intent treatment compared to the cost associated...

  • Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes. Stroupe, Kevin; Tarlov, Elizabeth; Weichle, Thomas; Zhang, Qiuying; Michaelis, Laura; Ozer, Howard; Durazo-Arvizu, Ramon; Hynes, Denise // Supportive Care in Cancer;Dec2014, Vol. 22 Issue 12, p3153 

    Purpose: Use of erythropoiesis-stimulating agents (ESAs) in US cancer care declined amidst post-marketing evidence of adverse effects and the Food and Drug Administration's (FDA) addition of a 'black-box' warning to product labeling in March 2007. Because reduced ESA use may have led to more...

  • Cancer news from ISPOR.  // PharmacoEconomics & Outcomes News;11/29/2008, Issue 567, p6 

    The article offers an overview of several cancer-related studies discussed at the 11th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conducted in Athens, Greece in November 2008. It includes the cost effectiveness of trastuzumab in...

  • Cost of lung cancer: a methodological review. Molinier, Laurent; Combescure, Christophe; Chouaîd, Cristos; Daurès, Jean-Pierre; Housset, Bruno; Fabre, Didier; Grand, Alain; Vergnenègre, Alain; Chouaïd, Cristos; Daurès, Jean-Pierre; Vergnenègre, Alain // PharmacoEconomics;2006, Vol. 24 Issue 7, p651 

    Cost of illness (COI) studies estimate the overall economic burden of a specific disease, rather than simply treatment-related costs. While having been criticised for not allowing resource prioritisation, COI studies can provide useful guidance, so long as they adhere to accepted methodology....

  • Cost-Effectiveness of CT Lung Cancer Screening.  // Radiology Today;Jun2012, Vol. 13 Issue 6, p13 

    The article discusses a study examining the costs and benefits of providing lung cancer screening through low-dose spiral computed tomography (CT) to people at high risk of lung cancer. According to the study, the cost per life-year saved would be lower than screening for cervical and breast...

  • Lung & Prostate Cancer News Headlines May 15, 2004-- June 14, 2004.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p10 

    Presents news headlines on lung and prostate cancer pharmaceutics for the period May 15 through June 14, 2004. Study showing Tarceva to increase survival rates of lung cancer patients; Final trial results for Iressa tablets as therapy for lung cancer patients; Data revealed by GTx for Acapodene...

  • Waging War On Lung Cancer. Brown, Ellen // FDA Consumer;May/Jun99, Vol. 33 Issue 3, p7 

    Focuses on lung cancer. Survival and detection; Diagnostic tests; Treatment; Future of lung cancer research; Findings, studies and developments related to lung cancer.

  • New Analysis Reexamines The Value Of Cancer Care In The United States Compared To Western Europe. Soneji, Samir; JaeWon Yang // Health Affairs;Mar2015, Vol. 34 Issue 3, p389 

    Despite sharp increases in spending on cancer treatment since 1970 in the United States compared to Western Europe, US cancer mortality rates have decreased only modestly. This has raised questions about the additional value of US cancer care derived from this additional spending. We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics